Singapore, May 26 -- HJ HyupJin, a South Korean healthcare and precision diagnostics company, and Inbiomotion, proprietors of MAF Test(R) for identifying high-risk early-stage breast cancer patients, have signed an agreement to start offering the MAF Test(R) in South Korea.

This agreement represents a new milestone for knowledge transfer at IRB Barcelona, as it is the first time a product born from research developed at the Institute has reached patients in South Korea.

The MAF Test(R) predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis....